Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity.
Direct intratumor injection of a disabled infectious single cycle HSV-2 virus encoding the murine GM-CSF gene (DISC/mGM-CSF) into established murine colon carcinoma CT26 tumors induced a significant delay in tumor growth and complete tumor regression in up to 70% of animals. Pre-existing immunity to HSV did not reduce the therapeutic efficacy of DISC/mGM-CSF, and, when administered in combination with syngeneic dendritic cells, further decreased tumor growth and increased the incidence of complete tumor regression. Direct intratumor injection of DISC/mGM-CSF also inhibited the growth of CT26 tumor cells implanted on the contralateral flank or seeded into the lungs following i.v. injection of tumor cells (experimental lung metastasis). Proliferation of splenocytes in response to Con A was impaired in progressor and tumor-bearer, but not regressor, mice. A potent tumor-specific CTL response was generated from splenocytes of all mice with regressing, but not progressing tumors following in vitro peptide stimulation; this response was specific for the gp70 AH-1 peptide SPSYVYHQF and correlated with IFN-gamma, but not IL-4 cytokine production. Depletion of CD8(+) T cells from regressor splenocytes before in vitro stimulation with the relevant peptide abolished their cytolytic activity, while depletion of CD4(+) T cells only partially inhibited CTL generation. Tumor regression induced by DISC/mGM-CSF virus immunotherapy provides a unique model for evaluating the immune mechanism(s) involved in tumor rejection, upon which tumor immunotherapy regimes may be based.
Ali
Selman A
SA
Department of Life Sciences, Nottingham Trent University, Nottingham, United Kingdom.
Lynam
June
J
McLean
Cornelia S
CS
Entwisle
Claire
C
Loudon
Peter
P
Rojas
José M
JM
McArdle
Stephanie E B
SE
Li
Geng
G
Mian
Shahid
S
Rees
Robert C
RC
D000818:Animals; D003110:Colonic Neoplasms / Q000276:immunology / Q000628:therapy*; D003131:Combined Modality Therapy; D003208:Concanavalin A / Q000494:pharmacology; D016207:Cytokines / Q000096:biosynthesis; D003602:Cytotoxicity, Immunologic / Q000235:genetics; D003713:Dendritic Cells / Q000637:transplantation; D000939:Epitopes / Q000235:genetics / Q000276:immunology*; D005260:Female; D005822:Genetic Vectors / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000235:genetics* / Q000276:immunology*; D006561:Herpes Simplex / Q000235:genetics / Q000276:immunology / Q000821:virology; D018259:Herpesvirus 1, Human / Q000235:genetics* / Q000276:immunology*; D007110:Immunity, Active / Q000235:genetics; D007279:Injections, Subcutaneous; D008213:Lymphocyte Activation / Q000235:genetics / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014775:Virus Activation / Q000235:genetics / Q000276:immunology
D016207:Cytokines; D000939:Epitopes; D003208:Concanavalin A; D016178:Granulocyte-Macrophage Colony-Stimulating Factor